Freenome is a biotechnology company that has pioneered the most comprehensive multiomics platform for early cancer detection. By combining a deep expertise in molecular biology with advanced computational biology and machine learning techniques to recognize disease-associated patterns among billions of circulating, cell-free biomarkers, Freenome is developing simple and accurate blood tests for early cancer detection and integrating the actionable insights into health systems to operationalize a machine learning feedback loop between care and science. Examples of Freenome’s novel research include advancing the fields understanding of using machine learning for early stage colorectal cancer detection featured at Digestive Disease Week and using cfDNA fragment coverage to predict gene expression featured at American Association for Cancer Research’s Annual Meeting.
| Date | Amount | Type | Investors | Valuation |
|---|---|---|---|---|
| 06/09/16 | $5,500,000 | Seed |
Data Collective Founders Fund Third Kind Venture Capital | undisclosed |
| 03/01/17 | $65,000,000 | Series A |
Charles River Ventures Data Collective Founders Fund Innovation Endeavors Polaris Partners Spectrum 28 | undisclosed |
| 08/28/17 | $7,000,000 | Series A Extension |
Anne Wojcicki Section 32  | undisclosed |
| 07/24/19 | $160,000,000 | Series B |
BrightEdge Ventures Data Collective Google Ventures Kaiser Permanente Ventures Perceptive Advisors Polaris Partners RA Capital Management Roche Venture Fund Section 32 T. Rowe Price Associates Verily Life Sciences | undisclosed |
| 08/26/20 | $270,000,000 | Series C |
Bain Capital Life Sciences Catalio Capital Management Colorectal Cancer Alliance Cormorant Asset Management EcoR1 Capital Farallon Capital Management Fidelity Management & Research Company Janus Henderson Investors Perceptive Advisors Rock Springs Capital | undisclosed |
| 12/07/21 | $300,000,000 | Series D |
A16z Artis Ventures Bain Capital Life Sciences BrightEdge Ventures Catalio Capital Cormorant Capital DCVC Farallon Capital Management Fidelity Management & Research Company GV Perceptive Advisors RA Capital Management | undisclosed |
| 01/11/22 | $290,000,000 | Venture |
Roche Venture Fund | undisclosed |
| 02/15/24 | $254,000,000 | Venture |
A16z ARK Invest ArrowMark Partners Artis Ventures Bain Capital Life Sciences BrightEdge Ventures Cormorant Capital DCVC Eventide Asset Management Intermountain Ventures Perceptive Advisors Polaris Partners Pura Vida Investments RA Capital Management Roche Venture Fund Sands Capital Section 32 | undisclosed |
